miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma

She,Xiaoling; Yu,Zhibin; Cui,Yulong; Lei,Qianqian; Wang,Zeyou; Xu,Gang; Xiang,Juanjuan; Wu,Minghua; Li,Guiyuan

doi:10.3892/or.2014.3318

miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma

Authors:
- Xiaoling She
- Zhibin Yu
- Yulong Cui
- Qianqian Lei
- Zeyou Wang
- Gang Xu
- Juanjuan Xiang
- Minghua Wu
- Guiyuan Li
View Affiliations

Affiliations: Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Hunan Cancer Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Cancer Research Institute, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: July 10, 2014 https://doi.org/10.3892/or.2014.3318
Pages: 957-964

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is one of the most deadly diseases affecting humans, and is often characterized by poor survival and by high resistance to chemotherapy and radiotherapy. Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of GBM following surgery. Although TMZ may restrain GBM growth, TMZ resistance is also common and accounts for numerous cases of treatment failure. Studies indicate that aberrant miRNA expression is associated with hallmark malignant properties of GBM. Thus, miRNA-based anticancer therapeutic approaches have been exploited, either alone or in combination with standard targeted therapies to enhance the efficacy of chemotherapy agents. In the present study, we demonstrated that the expression of miR-128 and miR-149 was downregulated in glioblastoma, and their overexpression inhibited the invasion of glioblastoma cells by targeting Rap1B-mediated cytoskeletal and related molecular alterations. Moreover, miR-128 and miR-149 enhanced the chemosensitivity of glioblastoma cells to TMZ.

View Figures

View References

1	Pichiorri F, Palmieri D, De Luca L, et al: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 210:951–968. 2013. View Article : Google Scholar : PubMed/NCBI
2	Pizzini S, Bisognin A, Mandruzzato S, et al: Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 14:5892013. View Article : Google Scholar : PubMed/NCBI
3	Yang J, Zhao H, Xin Y and Fan L: MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chen L, Zhang Y, Yang J, Hagan JP and Li M: Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta. 1836:158–165. 2013.PubMed/NCBI
5	Chou KN, Lin YC, Liu MY and Chang PY: Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. J Clin Neurosci. 21:701–704. 2013. View Article : Google Scholar : PubMed/NCBI
6	Danson SJ and Middleton MR: Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 1:13–19. 2001. View Article : Google Scholar : PubMed/NCBI
7	Stupp R, Gander M, Leyvraz S and Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2:552–560. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wong STS, Zhang XQ, Zhuang JTF, Chan HL, Li CH and Leung GKK: MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 32:2835–2841. 2012.PubMed/NCBI
9	Shi L, Chen JA, Yang JA, Pan TH, Zhang SG and Wang ZM: MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352:255–264. 2010. View Article : Google Scholar : PubMed/NCBI
10	Qian XM, Ren Y, Shi ZD, et al: Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm. 9:2636–2645. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ujifuku K, Mitsutake N, Takakura S, et al: miR-195, miR-455–3p and miR-10a* are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 296:241–248. 2010.
12	Slaby O, Lakomy R, Fadrus P, et al: MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 57:264–269. 2010. View Article : Google Scholar : PubMed/NCBI
13	Shi L, Zhang SG, Feng K, et al: MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 40:119–129. 2012.PubMed/NCBI
14	Li D, Chen P, Li XY, et al: Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I–III astrocytomas. OMICS. 15:673–682. 2011.PubMed/NCBI
15	Wittchen ES, Aghajanian A and Burridge K: Isoform-specific differences between Rap1A and Rap1B GTPases in the formation of endothelial cell junctions. Small GTPases. 2:65–76. 2011. View Article : Google Scholar : PubMed/NCBI
16	Nuovo GJ: In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods. 44:39–46. 2008. View Article : Google Scholar : PubMed/NCBI
17	Evangelisti C, Florian MC, Massimi I, et al: MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 23:4276–4287. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang Y, Chao T, Li R, et al: MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med. 87:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
19	Costa PM, Cardoso AL, Nobrega C, et al: MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet. 22:904–918. 2013. View Article : Google Scholar : PubMed/NCBI
20	Khan AP, Poisson LM, Bhat VB, et al: Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics. 9:298–312. 2010. View Article : Google Scholar : PubMed/NCBI
21	Weiss GJ, Bemis LT, Nakajima E, et al: EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA and Lodish HF: A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle. 9:1037–1042. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhu Y, Yu F, Jiao Y, et al: Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011. View Article : Google Scholar : PubMed/NCBI
24	Shi ZM, Wang J, Yan Z, et al: miR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One. 7:e327092012. View Article : Google Scholar : PubMed/NCBI
25	Lin RJ, Lin YC and Yu AL: miR-149^* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 49:719–727. 2010.PubMed/NCBI
26	Jin L, Hu WL, Jiang CC, et al: MicroRNA-149^*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA. 108:15840–15845. 2011.PubMed/NCBI
27	Wang Y, Zheng XS, Zhang ZY, et al: MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS One. 7:e416932012. View Article : Google Scholar : PubMed/NCBI
28	Tu HF, Liu CJ, Chang CL, et al: The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS One. 7:e516062012. View Article : Google Scholar : PubMed/NCBI
29	Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG and Sun BM: MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol. 25:871–881. 2012.PubMed/NCBI
30	Tang HL, Wang ZY, Liu XP, et al: LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets. 12:1032–1042. 2012. View Article : Google Scholar : PubMed/NCBI
31	Guo Y, Yan KP, Fang JS, Qu Q, Zhou M and Chen FH: Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res. 32:412013. View Article : Google Scholar : PubMed/NCBI
32	Pellegrino L, Stebbing J, Braga VM, et al: miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res. 41:5400–5412. 2013. View Article : Google Scholar : PubMed/NCBI
33	Avellino R, Carrella S, Pirozzi M, et al: miR-204 targeting of Ankrd13A controls both mesenchymal neural crest and lens cell migration. PLoS One. 8:e610992013. View Article : Google Scholar : PubMed/NCBI
34	Bockhorn J, Yee K, Chang YF, et al: MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 137:373–382. 2013. View Article : Google Scholar : PubMed/NCBI
35	Bertoni A, Tadokoro S, Eto K, et al: Relationships between Rap1b, affinity modulation of integrin αIIbβ3, and the actin cytoskeleton. J Biol Chem. 277:25715–25721. 2002.PubMed/NCBI
36	Malchinkhuu E, Sato K, Maehama T, et al: Role of Rap1B and tumor suppressor PTEN in the negative regulation of lysophosphatidic acid-induced migration by isoproterenol in glioma cells. Mol Biol Cell. 20:5156–5165. 2009. View Article : Google Scholar : PubMed/NCBI
37	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
38	de Toledo M, Anguille C, Roger L, Roux P and Gadea G: Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One. 7:e483442012.PubMed/NCBI
39	Feng H, Hu B, Liu KW, et al: Activation of Rac1 by Src-dependent phosphorylation of Dock180^Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest. 121:4670–4684. 2011. View Article : Google Scholar : PubMed/NCBI
40	Fortin Ensign SP, Mathews IT, Eschbacher JM, Loftus JC, Symons MH and Tran NL: The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2. J Biol Chem. 288:21887–21897. 2013.